Kahveci Orhan Kemal, Kuzu Selçuk, Altıntaş Mustafa, Vurmaz Ayhan, Çelik Sefa
Department of Otorhinolaryngology, Afyon Health Sciences University Medical Faculty, Afyonkarahisar, Turkey.
ENT Clinic, Serik State Hospital, Antalya, Turkey.
Am J Rhinol Allergy. 2021 Jan;35(1):52-58. doi: 10.1177/1945892420932768. Epub 2020 Jun 19.
The purpose of this study is to determine the post-treatment levels of total oxidant status (TOS) and total antioxidant status (TAS), that are increased due to pathophysiology, and to compare those with pre-treatment levels in allergic rhinitis patients. Among 84 patients clinically diagnosed with allergic rhinitis, 31 patients were started only on nasal steroid treatment (mometasone furoate), and 53 patients were started on nasal steroid and oral antihistamine treatment (mometasone furoate + rupatadine fumarate 10 mg). Blood samples were taken from the patients at the first examination and at post-treatment month 1.TAS and TOS were measured from the blood samples.
While no significant change was determined in mean TAS levels with treatment, a statistically significant decrease was determined in TOS values in post-treatment period (P < .01). There was no significant change in TAS and TOS values of patients only using nasal steroids, while a significant decrease was determined in post-treatment TOS values of patients using both nasal steroids and oral antihistamines (P < .001). It was determined that TOS values of women were significantly lower compared to men, and it was also reduced in seasonal allergic rhinitis compared to perennial allergic rhinitis (P < .05 for both).
In allergic rhinitis patients, concomitant use of nasal steroids and antihistamines significantly decreases total oxidative stress. It may be stated that the addition of antihistamines to allergic rhinitis treatment positively affects treatment.
本研究的目的是确定因病理生理学而升高的总氧化剂状态（TOS）和总抗氧化剂状态（TAS）的治疗后水平，并将其与过敏性鼻炎患者的治疗前水平进行比较。在84例临床诊断为过敏性鼻炎的患者中，31例仅开始使用鼻用类固醇治疗（糠酸莫米松），53例开始使用鼻用类固醇和口服抗组胺药治疗（糠酸莫米松+10毫克富马酸卢帕他定）。在首次检查时和治疗后第1个月采集患者的血样。从血样中测量TAS和TOS。
治疗后平均TAS水平无显著变化，但治疗后TOS值有统计学意义的下降（P<0.01）。仅使用鼻用类固醇的患者的TAS和TOS值无显著变化，而同时使用鼻用类固醇和口服抗组胺药的患者治疗后TOS值有显著下降（P<0.001）。确定女性的TOS值显著低于男性，季节性过敏性鼻炎患者的TOS值也低于常年性过敏性鼻炎患者（两者均P<0.05）。
在过敏性鼻炎患者中，同时使用鼻用类固醇和抗组胺药可显著降低总氧化应激。可以说，在过敏性鼻炎治疗中添加抗组胺药对治疗有积极影响。
